PXD016166

PXD016166 is an original dataset announced via ProteomeXchange.

Title	Elevated Levels of Arsenic Trioxide Promote Divergent SUMOylation
Description	ATO is a therapeutic agents used to treat APL, a disease caused by a chromosomal translocation of the RARα gene that can occur reciprocally with the PML gene. The mechanisms through which ATO function and how increased levels of ATO adversely affect the cell are not fully characterized though they involve the SUMOylation, the ubiquitylation and the degradation of the PML/RARα oncoprotein through the PML moiety. Changes in protein SUMOylation, phosphorylation and ubiquitylation were profiled using large-scale proteomic workflows on HEK293 cells following exposure to typical (1 μM) or elevated (10 μM) ATO for 4h to understand the mechanism that underlies the cytotoxicity induced with important ATO levels. Our analyses revealed that 88 proteins displayed divergent SUMOylation with elevated ATO compared to the lower dose, where the latter caused changes in SUMOylation of 4 proteins, including PML. Some of these differing SUMOylation events occurred on known substrates of caspase-3. A similar phenomenon was observed in the phosphoproteomic studies, where 48 proteins were specifically regulated with elevated ATO levels, while low ATO doses barely altered the phosphoproteome. Elevated levels of ATO cause the erroneous SUMOylation and phosphorylation of a vast amount of substrates, which may be responsible for its cytotoxic effects.
HostingRepository	PRIDE
AnnounceDate	2020-04-06
AnnouncementXML	Submission_2020-04-05_23:23:37.xml
DigitalObjectIdentifier
ReviewLevel	Peer-reviewed dataset
DatasetOrigin	Original dataset
RepositorySupport	Unsupported dataset by repository
PrimarySubmitter	Francis McManus
SpeciesList	scientific name: Homo sapiens (Human); NCBI TaxID: 9606;
ModificationList	phosphorylated residue; sumoylated lysine; monohydroxylated residue; iodoacetamide derivatized residue
Instrument	Q Exactive

Revision	Datetime	Status	ChangeLog Entry
0	2019-11-06 02:05:43	ID requested
⏵ 1	2020-04-05 23:23:38	announced

Rinfret Robert C, McManus FP, Lamoliatte F, Thibault P, Interplay of Ubiquitin-Like Modifiers Following Arsenic Trioxide Treatment. J Proteome Res, 19(5):1999-2010(2020) [pubmed]

submitter keyword: Arsenic trioxide, Caspase, LC-MS, PARP1, Post-translational modifications, SUMOylation, Phosphoproteomics.

Pierre Thibault
contact affiliation	Institute for Research in Immunology and Cancer, Québec, Canada
contact email	pierre.thibault@umontreal.ca
lab head
Francis McManus
contact affiliation	University of Montreal
contact email	francispmcmanus@gmail.com
dataset submitter

Dataset FTP location NOTE: Most web browsers have now discontinued native support for FTP access within the browser window. But you can usually install another FTP app (we recommend FileZilla) and configure your browser to launch the external application when you click on this FTP link. Or otherwise, launch an app that supports FTP (like FileZilla) and use this address: ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/04/PXD016166

PRIDE project URI

• PRIDE
  1. PXD016166
     1. Label: PRIDE project
     2. Name: Elevated Levels of Arsenic Trioxide Promote Divergent SUMOylation